An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added.
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added. The spray’s ...
Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added. The spray’s ...